Denali Therapeutics Announces Pricing of Initial Public Offering
December 07, 2017 19:08 ET
|
Denali Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its initial public offering of 13,888,888 shares of its common...
DiamiR Announces Oral Presentation at AD/PD(TM) 2017
March 29, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 29, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Samuil...
DiamiR to Present at the GTCbio Biomarker Summit 2017
March 20, 2017 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 20, 2017) - DiamiR, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, today announced that Kira...
DiamiR Announces Oral Presentation at Biomarkers Summit 2016
March 18, 2016 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - March 18, 2016) - DiamiR, LLC, a developer of innovative minimally invasive diagnostic tests for neurodegenerative and other diseases, announced today that...
Jackson Laboratory researchers discover mutation involved in neurodegeneration
October 06, 2015 08:52 ET
|
The Jackson Laboratory
BAR HARBOR, Maine, Oct. 6, 2015 (GLOBE NEWSWIRE) -- A mutation that increases the level of a special class of sphingolipids—molecules important to cell structure and signaling—can lead to...
Vaccinex Announces the Publication of Data Demonstrating Preclinical Efficacy in an Animal Model of Huntington Disease
February 17, 2015 11:05 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 17, 2015 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage immunotherapy company engaged in the discovery and development of therapeutic monoclonal antibodies, today announced...
DiamiR Announces Poster Presentation at the Clinical Trials on Alzheimer's Disease 2014
November 17, 2014 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - November 17, 2014) - DiamiR Biosciences, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the company's...
DiamiR Announces Publication and Discusses Merits of Universal Screening Test Based on Organ-Enriched microRNA Signatures
November 03, 2014 08:02 ET
|
DiamiR Biosciences Corp.
MONMOUTH JUNCTION, NJ--(Marketwired - November 03, 2014) - DiamiR Biosciences Corp., a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today the...
DiamiR Announces Corporate Presentation at Life Sciences Summit 2014
October 22, 2014 08:02 ET
|
DiamiR LLC
MONMOUTH JUNCTION, NJ--(Marketwired - October 22, 2014) - DiamiR Biosciences, a developer of innovative diagnostic tests for neurodegenerative and other diseases, announced today that the company's...
DiamiR Announces Grant From The Michael J. Fox Foundation for Parkinson's Research to Advance Assessment of Brain-Enriched microRNA Biomarkers in Plasma
July 14, 2014 11:00 ET
|
DiamiR LLC
MONMOUTH JUNCTION, NJ--(Marketwired - July 14, 2014) - DiamiR, LLC, a molecular diagnostics company focused on the development and commercialization of innovative tests for detection and monitoring...